Patent intelligence · US
US 11312939
Constructs for chimeric antigen receptors
Constructs for chimeric antigen receptors
Patent details — US 11312939
- Jurisdiction
- US
- Status
- granted
- Grant date
- Apr 26, 2022
- Expiration
- Apr 21, 2042
- Applicant
- Carisma Therapeutics Inc.
- Claims
- 25
- CPC classes
- A61K, A61K2239/13, A61K2239/21, A61K2239/22
Quick answer
US 11312939 (Constructs for chimeric antigen receptors) is held by Carisma Therapeutics Inc.. Status: granted. Granted Apr 26, 2022. Expires Apr 21, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Carisma Therapeutics Inc.
- Grant date
- Expiration
- Claims
- 25
- CPC classes
- A61K, A61K2239/13, A61K2239/21, A61K2239/22, A61K38/00, A61K40/17
More from Carisma Therapeutics Inc.
Related pharmaceutical patents in our USPTO index.
Frequently asked questions
What is US patent 11312939?
US 11312939 (Constructs for chimeric antigen receptors) is held by Carisma Therapeutics Inc.. Status: granted. Granted Apr 26, 2022. Expires Apr 21, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11312939?
Carisma Therapeutics Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 2 pharmaceutical patents for this assignee.
When does US 11312939 expire?
Our index shows an expiration date of Apr 21, 2042 (16 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.